Hostname: page-component-6766d58669-h8lrw Total loading time: 0 Render date: 2026-05-21T09:57:35.170Z Has data issue: false hasContentIssue false
  • English
  • Français

Expression of cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2 in patients with primary laryngeal carcinoma: a tissue microarray study

Published online by Cambridge University Press:  21 September 2007

P Dong ,
X Li ,
Z Yu  and
G Lu
P Dong*
Affiliation:
Department of Otolaryngology-Head & Neck Surgery, Shanghai Jiao Tong University, Affiliated Shanghai First People's Hospital, China
X Li
Affiliation:
Department of Otolaryngology-Head & Neck Surgery, Shanghai Jiao Tong University, Affiliated Shanghai First People's Hospital, China
Z Yu
Affiliation:
Department of Otolaryngology-Head & Neck Surgery, Shanghai Jiao Tong University, Affiliated Shanghai First People's Hospital, China
G Lu
Affiliation:
Department of Otolaryngology-Head & Neck Surgery, Shanghai Jiao Tong University, Affiliated Shanghai First People's Hospital, China
*
Address for correspondence: Dr Pin Dong, Department of Otolaryngology-Head and Neck Surgery, Shanghai Jiaotong University, Affiliated First People's Hospital, Shanghai 200080, China. Fax: +86 021 63240825 E-mail: dongpin64@yahoo.com.cn
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To determine the correlation between expression of cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2, in patients with laryngeal carcinoma.

Design:

The study included 85 primary laryngeal squamous cell carcinoma cases. Expression was assessed using Envision immunohistochemical stains for cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2.

Subjects:

A tissue microarray containing samples from the 85 primary laryngeal squamous cell carcinoma cases was assembled. Immunohistochemical testing for cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2 was performed. Using Pearson correlation, expression of these proteins was compared with the following clinicopathological variables: age, sex, clinical tumour–node–metastasis staging, and prognosis. Three-year survival curves, factored by cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2 expression, were generated for overall survival, by Kaplan–Meier analysis.

Results:

The expression of cyclooxygenase-2 significantly differed between patients with different pathology, tumour–node–metastasis stage and prognosis. A marked difference in vascular endothelial growth factor expression was seen between two histological grade groups. Expression of matrix metalloproteinase-2 protein statistically significantly differed between patients with different tumour–node–metastasis stages, lymph node metastases and three-year survival rates. The expression of cyclooxygenase-2 in laryngeal carcinoma tissue was found to be associated with the expression of matrix metalloproteinase-2.

Conclusion:

Cyclooxygenase-2 and matrix metalloproteinase-2 may act as clinical prognostic indicators of tumour growth and differentiation in laryngeal carcinoma.

Keywords

Microarray AnalysisHead and Neck NeoplasmsLarynx NeoplasmsImmunohistochemistryCOX-2MMP-2AngiogenesisPrognosis

Information

Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 121 , Issue 12 , December 2007 , pp. 1177 - 1183
Copyright
Copyright © JLO (1984) Limited 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1 Lin, CC, Kenyon, L, Hyslop, T, Hammond, E, Andrews, DW, Curran, WJ Jr et al. Cyclooxygenase-2 (COX-2) expression in human meningioma as a function of tumor grade. Am J Clin Oncol 2003;26:98–102CrossRefGoogle ScholarPubMed
2 Bodey, B, Siegel, SE, Kaiser, HE. Cyclooxygenase-2 (COX-2) overexpression in childhood brain tumors. In Vivo 2006;20:519–25Google ScholarPubMed
3 Chan, G, Boyle, JO, Yang, EK, Zhang, F, Sacks, PG, Shah, JP et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of head and neck. Cancer Res 1999;59:991–4Google Scholar
4 Li, W, Xu, RJ, Zhang, HH, Jiang, LH. Overexpression of cyclooxygenase-2 correlates with tumor angiogenesis in endometrial carcinoma. J Gynecol Cancer 2006;16:1673–8CrossRefGoogle ScholarPubMed
5 Miura, S, Tatsuguchi, A, Wada, K, Takeyama, H, Shinji, Y, Hiratsuka, T et al. Cyclooxygenase-2-regulated vascular endothelial growth factor release in gastric fibroblasts. Am J Physiol Gastrointest Liver Physiol 2004;287:G444–51CrossRefGoogle ScholarPubMed
6 Abe, M, Sato, Y. cDNA microarray analysis of the gene expression profile of VEGF-activated human umbilical vein endothelial cells. Angiogenesis 2001;4:289–98CrossRefGoogle ScholarPubMed
7 Miyata, Y, Koga, S, Kanda, S, Nishikido, M, Hayashi, T, Kanetake, H. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 2003;9:1741–9Google ScholarPubMed
8 Attiga, FA, Fernandez, PM, Weeraratna, AT, Manyak, MJ, Patierno, SR. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000;60:4629–37Google ScholarPubMed
9 Sivula, A, Talvensaari-Mattila, A, Lundin, J, Joensuu, H, Haglund, C, Ristimaki, A et al. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 2005;89:215–20CrossRefGoogle ScholarPubMed
10 Kuwamori, T, Rao, CV, Seibert, K, Reddy, BS. Chemopreventive activity of celeCOXib, a specific cyclooxygenese-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409–12Google Scholar
11 Wan, WH, Fortuna, MB, Furmanski, P. A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J Immunol Methods 1987;103:121–9Google ScholarPubMed
12 Jemal, A, Siegel, R, Ward, E, Murray, T, Xu, J, Thun, MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66CrossRefGoogle Scholar
13 Kononen, J, Bubendorf, L, Kallioniemi, A, Barlund, M, Schraml, P, Leighton, S et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844–7CrossRefGoogle ScholarPubMed
14 Mobasheri, A, Airley, R, Hewitt, SM, Marples, D. Heterogeneous expression of the aquaporin 1 (AQP1) water channel in tumors of the prostate, breast, ovary, colon and lung: a study using high density multiple human tumor tissue microarrays. J Oncol 2005;26:1149–58Google Scholar
15 Bhargava, R, Lal, P, Chen, B. Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma. Diagn Mol Pathol 2004;13:213–16CrossRefGoogle ScholarPubMed
16 Koynova, DK, Tsenova, VS, Jankova, RS, Gurov, PB, Toncheva, DI. Tissue microarray analysis of EGFR and HER2 oncogene copy number alterations in squamous cell carcinoma of the larynx. J Cancer Res Clin Oncol 2005;131:199–203CrossRefGoogle ScholarPubMed
17 Freier, K, Bosch, FX, Flechtenmacher, C, Devens, F, Benner, A, Lichter, P et al. Distinct site-specific oncoprotein overexpression in head and neck squamous cell carcinoma: a tissue microarray analysis. Anticancer Res 2003;23:3971–7Google ScholarPubMed
18 Peters, S, Hambek, M, Gstottner, W, Knecht, R. Tissue microarrays. Value of immunohistochemical proliferation markers for serial investigations of head and neck cancer [in German]. HNO 2004;52:409–12Google ScholarPubMed
19 Young-Ae, C, Dong-jun, L, Hyung-Kyu, L, Jae-Ho, J, Jong-Kyung, S, Shin-Sung, K et al. Interleukin-1β stimulates matrix metalloproteinase-2 expression via prostaglandin E2-dependent mechanism in human chondrocytes. Experimental and Molecular Medicine 2004;36:226–32Google Scholar
20 Del Bufalo, D, Trisciuoglio, D, Scarsella, M, D'Amati, G, Candiloro, A, Iervolino, A et al. Lonidamine causes inhibition of angiogenesis-related endothelial cell functions. Neoplasia 2004;6:513–22CrossRefGoogle ScholarPubMed
21 Lara-Pezzi, E, Gomez-Gaviro, MV, Galvez, BG, Mira, E, Iniguez, MA, Fresno, M et al. The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase 2 expression. J Clin Invest 2002;110:1821–8CrossRefGoogle ScholarPubMed
22 Williams, CS, Mann, M, Dubois, RN. The role of cyclooxygenases in inflammation, cancer and development. Oncogene 1996;18:7908–16CrossRefGoogle Scholar
23 Theret, N, Musso, O, Turlin, B, Lotrian, D, Bioulac-Sage, P, Campion, JP et al. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 2001;34:82–8CrossRefGoogle ScholarPubMed
24 Sano, H, Kawahito, Y, Wilder, RL, Hashiramoto, A, Mukai, S, Asai, K et al. Expression of cyclooxygenase-1 and 2 in human colorectal cancer. Cancer Res 1995;55:3785–9Google ScholarPubMed
25 Gallo, O, Franchi, A, Magnelli, L, Sardi, I, Vannacci, A, Boddi, V et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer: implications for tumor angiogenesis and metastases. Neoplasia 2001;3:53–61CrossRefGoogle Scholar
26 Shintani, S, Li, C, Ishikawa, T, Mihara, M, Nakashiro, K, Hamakawa, H. Expression of vascular endothelial growth factor A, B, C and D in oral squamous cell carcinoma. Oral Oncol 2004;40:13–20CrossRefGoogle Scholar
27 Callejas, NA, Casado, M, Diaz-Guerra, MJ, Bosca, L, Martin-Sanz, P. Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology 2001;33:860–7CrossRefGoogle ScholarPubMed
28 Shankavaram, UT, Lai, WC, Netzel-Arnett, S, Mangan, PR, Ardans, JA, Caterina, N et al. Monocyte membrane type 1-matrix metalloproteinase. Prostaglandin-dependent regulation and role in metalloproteinase-2 activation. J Bio Chem 2001;276:19027–32CrossRefGoogle ScholarPubMed
29 Choi, EY, Kim, D, Hong, BK, Kwon, HM, Song, YG, Byun, KH et al. Upregulation of extracellular matrix metalloproteinase inducer (EMMPRIN) and gelatinases in human atherosclerosis infected with Chlamydia pneumoniae. The potential role of Chlamydia pneumoniae infection in the progression of atherosclerosis. Exp Mol Med 2002;34:391–400CrossRefGoogle ScholarPubMed
30 Smalley, W, Du Bois, RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997;39:1–20CrossRefGoogle ScholarPubMed
31 Sheng, H, Shao, J, Kirkland, SC, Isakson, P, Coffey, RJ, Morrow, J et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254–9CrossRefGoogle ScholarPubMed
32 Ondrey, FG, Juhn, SK, Adams, GL. Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. Laryngoscope 1996;106:129–34CrossRefGoogle ScholarPubMed
33 Scioscia, KA, Snyderman, CH, Rueger, R, Reddy, J, D'Amico, F, Comsa, S et al. Role of arachidonic acid metabolites in tumor growth inhibition by nonsteroidal anti-inflammatory drugs. Am J Otolaryngol 1997;18:1–8CrossRefGoogle Scholar
34 Panje, WR. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol 1998;107:658–63CrossRefGoogle Scholar